PIM1 Antibody (YA2502)(PBS only)
(Synonyms: PIM1; Serine/threonine-protein kinase pim-1)PIM1 Antibody (YA2502) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PIM1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:100 |
Product Details
PIM1 Antibody (YA2502) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PIM1.
-
Host Rabbit
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 36 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 36 kDa
A synthetic peptide of human PIM1
Affinity Purified
Non-conjugated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis was performed on extracts from Hela (lane 1, 15 μg), HL-60 (lane 2, 15 μg), and 293T (lane 3, 15 μg) using PIM1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Actin, HY-P80438, 1:5000 dilution) was incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C. -
Immunohistochemical analysis of paraffin-embedded human Breast Cancer tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Immunohistochemical analysis of paraffin-embedded human Colon cancer tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Immunohistochemical analysis of paraffin-embedded human Prostate Cancer tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Immunohistochemical analysis of paraffin-embedded human Cervical cancer tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Immunohistochemical analysis of paraffin-embedded human Testis tissue using PIM1 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P82757, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Colon cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Colon cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Colon cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium. -
Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Prostate Cancer tissue using PIM1 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P82757, 1:200 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)（HY-D1832）. The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
Background
-
Function
PIM1 is a constitutively active serine/threonine kinase that regulates cell survival, proliferation, cell-cycle progression, and apoptosis through phosphorylation of multiple downstream substrates involved in oncogenic signaling networks[1]. Mechanistically, PIM1 functions downstream of cytokine-responsive pathways, particularly JAK/STAT signaling, and cooperates with pathways including PI3K/AKT/mTOR, MYC, and NF-κB to promote cellular growth, metabolic adaptation, and resistance to stress signals[2][3]. In disease contexts, PIM1 is frequently overexpressed in hematologic malignancies, prostate cancer, and several solid tumors, where elevated activity is associated with tumor progression, survival advantages, and therapeutic resistance[3][4]. Experimental studies further demonstrate that PIM1 contributes to tumorigenicity, cellular migration, invasion, and maintenance of aggressive cancer phenotypes, supporting its value as a mechanistic target in cancer biology research[5][6]. Compared with the related isoforms PIM2 and PIM3, PIM1 shares a highly conserved catalytic domain and overlapping substrate specificity, yet displays distinct expression patterns and context-dependent biological functions that influence disease phenotypes and therapeutic responses[7][8]. For experimental applications, the unique ATP-binding pocket of PIM kinases has enabled development of selective and pan-PIM inhibitors, including SGI-1776, AZD1208, CX-6258, and TP-3654, which are widely used to investigate PIM-dependent signaling, proliferation, apoptosis, and drug-resistance mechanisms in preclinical models[3][7][9].
-
Subcellular Localization
Cytoplasm; Nucleus; Cell membrane
-
Expression
Tissue_specificity:Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines
Induction:By interferon-gamma (IFNG) (PubMed:37797010) . Strongly induced in leukocytes by the JAK/STAT pathway in response to cytokines. Induced by different cellular stresses, heat shock and cytotoxic agents (PubMed:15528381, PubMed:15798097, PubMed:16186805) -
Isoforms & Post-Translational Modification
P11309 has 2 isomers: P11309-1: 35686 Da (predicted); P11309-2: 45412 Da (predicted).
Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation;Ubiquitinated, leading to proteasomal degradation -
Subunit
Interacts with HSP90AA1, this interaction stabilizes PIM1 protein levels (PubMed:15798097). Interacts (ubiquitinated form) with HSP70 and promotes its proteasomal degradation (PubMed:15798097)
-
SwissProt ID
-
Synonyms
PIM1; Serine/threonine-protein kinase pim-1
-
Research Field
Signal Transduction
Documentation
References
[1]. Uniprotkb.
[2]. Gonzalez-Fajardo L, et al. Reduced in vivo toxicity of doxorubicin by encapsulation in cholesterol-containing self-assembled nanoparticles. Pharmacol Res. 2016 May;107:93-101. [Content Brief]
[3]. Bellon M, et al. Targeting Pim kinases in hematological cancers: molecular and clinical review. Mol Cancer. 2023 Jan 25;22(1):18. [Content Brief]
[4]. Luszczak S, et al. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduct Target Ther. 2020 Jan 31;5(1):7. [Content Brief]
[5]. Wang J, et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene. 2012 Apr 5;31(14):1794-803. [Content Brief]
[6]. Santio NM, et al. PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins. Cell Commun Signal. 2020 Aug 8;18(1):121. [Content Brief]
[7]. Mennati A, et al. Dual silencing of integrin αvβ3 receptor and insulin-like growth factor 1 receptor using mPEG-PCL/DDAB hybrid nanoparticle loaded siRNA in breast cancer therapy: An in vitro study on MCF-7 cells. Int J Biol Macromol. 2025 Mar;294:139334. [Content Brief]
[8]. Rathi A, et al. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochim Biophys Acta Gen Subj. 2021 Nov;1865(11):129995. [Content Brief]
[9]. Haddach M, et al. Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor. ACS Med Chem Lett. 2011 Dec 27;3(2):135-9. [Content Brief]
Powered by Bioz
